Cardiff Oncology

Did you know that 1 in 8 women in the United States will be diagnosed with #breastcancer in her lifetime? October is #breastcancerawarenessmonth! At Cardiff Oncology, we are committed to advancing cancer care through innovative research and breakthrough treatments across a range of #cancer types. This month, we stand in solidarity with those impacted by breast cancer and support ongoing efforts to improve diagnosis, treatment, and survival outcomes. For more resources, please visit the National Breast Cancer Foundation, Inc.: https://lnkd.in/etpVpWV

Please join us in celebrating our CEO, Mark Erlander, Ph.D., for being a 2024 #PharmaVoice100 honoree! This prestigious recognition celebrates individuals from the #lifesciences industry who are making meaningful contributions to their field and striving to improve patient outcomes. Dr. Erlander’s visionary leadership and unwavering dedication to finding new cancer therapies serve as a beacon for our employees and other industry leaders. A heartfelt thank you to PharmaVoice for recognizing Dr. Erlander’s contributions, and congratulations to all the honorees making a difference in #healthcare. Read the full list here: https://lnkd.in/e9pFrenZ #PV100

Data alert! Preclinical data published recently in Cancers MDPI explore the combination of Cardiff Oncology’s PLK1 inhibitor onvansertib and the PI3K inhibitor alpelisib in HR-positive #breastcancer models resistant to endocrine therapy and CDK4/6 inhibitors. The study demonstrates that onvansertib synergizes with alpelisib, resulting in more effective tumor growth inhibition and induction of apoptosis than either treatment alone. These findings provide evidence for a potential new therapeutic strategy for HR+ breast cancer patients resistant to first-line therapies. Read the full article here: https://lnkd.in/efzjxest Congrats to team members Sreeja Sreekumar, PhD, Davis Klein, Migdalia Gonzalez, Tod Smeal, Ph.D. and Maya Ridinger, PhD for your incredible contributions. #oncology #innovation

Did you know that, according to the American Cancer Society, 1 in every 87 women in the United States will be diagnosed with #ovariancancer? Recent preclinical research demonstrated that our PLK1 inhibitor, onvansertib, when combined with the PARP inhibitor Olaparib, inhibits tumor growth in ovarian cancer cells that are resistant to PARP inhibitors. PARP inhibitor-resistant cancers are difficult to treat, but we are hopeful that new therapeutics can revolutionize the current standard of care. At Cardiff Oncology, we’re committed to pushing the boundaries of what’s possible in #cancer care to enhance outcomes for all. For more resources, please visit National Ovarian Cancer Coalition: https://ovarian.org/. #NOCAM2024 #KnowOvarian #Ovariancancerawareness

How does a neuroscience Ph.D. end up as the head of an early-stage oncology company??We'll let our CEO Mark Erlander, Ph.D. tell you. ??? If you haven’t yet, be sure to watch the full #interview with Michael Pietrack on The Pharmaverse Podcast. Mark delves into his journey to Cardiff Oncology, his leadership philosophy, and offers a glimpse into the future of #cancertreatments, including targeted therapies and personalized medicine. Watch now: https://lnkd.in/et_cUbaQ #oncology #leadershipdevelopment #podcast

Our Chief Medical Officer, Dr. Fairooz Kabbinavar M.D., FACP, sat down with Clinical Leader to discuss a pivotal moment in Cardiff Oncology’s journey—our decision to transition our lead clinical development program from second-line to first-line RAS-mutated metastatic #colorectalcancer. In this Q&A, Dr. Kabbinavar shares the data that drove this decision, the collaborative conversations with the #FDA, and what this could mean for the future of mCRC treatment and patients. Interested in the strategy behind #clinicaltrial design? Then this interview is a must-read! https://lnkd.in/eMU-DemU #innovation #cancerresearch

What a turnout! Last weekend, the Cardiff Oncology team and their families joined the San Diego #WalktoEndColonCancer. This was a fantastic opportunity to support the #colorectalcancer community and the local community. For our second year participating in this event, the experience was truly inspiring, and we are already looking forward to next year! Our team proudly sponsored this event and, together, raised funds to support the Colorectal Cancer Alliance's prevention, support and research efforts. Thanks to everyone who contributed to this worthwhile event. Let's #WalkLoud every day as we strive to end #coloncancer. #colorectalcancerawareness

This just in! We’ve released our Q2 results and business update. ? ?? We've made significant strides in our lead program for first-line RAS-mutated metastatic #colorectalcancer. With 33 sites open for enrollment and the support from our clinical execution partner, Pfizer Ignite, we anticipate the initial readout from the randomized CRDF-004 trial later this year. ? ?? Our first-line metastatic #pancreaticcancer program will combine onvansertib with standard of care NALIRIFOX in a new investigator-initiated trial. ? ?? Preclinical data highlights onvansertib’s potential to overcome resistance to PARP inhibitors in high-grade serous #ovariancancer. This, coupled with the five abstracts our team presented at #AACR24, underscores the rationale for onvansertib's development across multiple tumor types and combination therapies. ? Read more: https://lnkd.in/ecTnwrBn #CancerResearch #Oncology

?? Save the date! Cardiff Oncology will release its financial results for the second quarter of 2024 and host a conference call and webcast on August 8 at 4:30 p.m. ET. ? The live webcast can be accessed through the link in the comment section below. The recording will be accessible on our website following the call. Learn more: https://lnkd.in/eB79hxN3 ? #CancerResearch #Oncology

Preclinical data published this week examines onvansertib's ability to overcome resistance to PARP inhibitors in high-grade serous #ovariancancer. Our data were generated in #ovariancancer models that are resistant to the PARP inhibitor olaparib. The data showed that the combination of onvansertib, our PLK1 inhibitor, and olaparib inhibits tumor growth and prolongs survival, effectively resensitizing ovarian cancer tumors to treatment. These findings underscore the potential of onvansertib to meet the significant unmet need in the treatment of PARP inhibitor-resistant cancers. Congrats to Cardiff Oncology team members Divora Yemane, Anju Karki, PhD, and Maya Ridinger, PhD for their contributions. Nice work, team! Read the full text article: https://bit.ly/3WjLCEO #oncology #drugdevelopment